How does NFAT3 regulate the occurrence of cardiac hypertrophy?

Wang Hui; Su Wenhua; Zhang Shuojie; Wang Lulin; Zhao Panpan; Zhang Tongtong; Xie Xiaoli; Dan Juhua

doi:10.1016/j.ijcha.2023.101271

How does NFAT3 regulate the occurrence of cardiac hypertrophy?

Int J Cardiol Heart Vasc. 2023 Sep 20:48:101271. doi: 10.1016/j.ijcha.2023.101271. eCollection 2023 Oct.

Authors

Wang Hui¹, Su Wenhua^{1

2}, Zhang Shuojie¹, Wang Lulin¹, Zhao Panpan¹, Zhang Tongtong¹, Xie Xiaoli¹, Dan Juhua¹

Affiliations

¹ Laboratory of Molecular Genetics of Aging & Tumor, Medical School, Kunming University of Science and Technology, Kunming, Yunnan, China.
² Department of Cardiology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.

Abstract

Cardiac hypertrophy is initially an adaptive response to physiological and pathological stimuli. Although pathological myocardial hypertrophy is the main cause of morbidity and mortality, our understanding of its mechanism is still weak. NFAT3 (nuclear factor of activated T-cell-3) is a member of the nuclear factor of the activated T cells (NFAT) family. NFAT3 plays a critical role in regulating the expression of cardiac hypertrophy genes by inducing their transcription. Recently, accumulating evidence has indicated that NFAT3 is a potent regulator of the progression of cardiac hypertrophy. This review, for the first time, summarizes the current studies on NFAT3 in cardiac hypertrophy, including the pathophysiological processes and the underlying pathological mechanism, focusing on the nuclear translocation and transcriptional function of NFAT3. This review will provide deep insight into the pathogenesis of cardiac hypertrophy and a theoretical basis for identifying new therapeutic targets in the NFAT3 network.

Keywords: Cardiac hypertrophy; NFAT3; Nuclear translocation.

Publication types

Review